Degarelix Acetate Patent Expiration
Degarelix Acetate is used for managing advanced prostate cancer and reducing side effects associated with GnRH agonist therapy. It was first introduced by Ferring Pharmaceuticals Inc
Degarelix Acetate Patents
Given below is the list of patents protecting Degarelix Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Firmagon | US10695398 | Method of treating prostate cancer with GnRH antagonist | Apr 27, 2032 | Ferring |
| Firmagon | US11766468 | Method of treating prostate cancer with GnRH antagonist | Apr 27, 2032 | Ferring |
| Firmagon | US11826397 | Method of treating prostate cancer with GnRH antagonist | Apr 27, 2032 | Ferring |
| Firmagon | US9415085 | Method of treating prostate cancer with GnRH antagonist | Apr 27, 2032 | Ferring |
| Firmagon | US10729739 | Methods of treating prostate cancer with GnRH antagonist | Feb 10, 2029 | Ferring |
| Firmagon | US10973870 | Methods of treating prostate cancer with GnRH antagonist | Feb 10, 2029 | Ferring |
| Firmagon | US9579359 | Method of treating prostate cancer with GnRH antagonist | Feb 10, 2029 | Ferring |
| Firmagon | US5925730 | GnRH antagonists |
May 18, 2021
(Expired) | Ferring |
Degarelix Acetate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List